A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients

- Stage I, II, or III primary non-small cell lung, primary breast, or primary ovarian cancer.

- Planning to start treatment with a taxane-based chemotherapy as part of one of the study-approved taxane regimens within 14 days after reg. See Appendix 18.1 for the study-approved docetaxel and paclitaxel-based regimens.

- Treatment on another clinical trial is allowed if it is one of the study-approved regimens listed in Appendix 18.1. Additional treatments (i.e., experimental therapy, immunotherapy, biologics, etc.) as part of another clinical trial in addition to any regimen approved in this study is allowed.

- No prior taxane, platinum, vinca alkaloid, or bortezomib-based chemotherapy regimen. (Carboplatin-containing regimen after reg as part of the docetaxel or paclitaxel regimen is allowed.)

- >/= 18 years of age.

- Must be able to complete Patient-Reported Outcome (PRO) instruments in English or Spanish. Must: 1) agree to complete PROs at all scheduled assessments; and 2) complete the baseline PRO forms prior to reg.

- Pre-existing neuropathy is allowed (incl. diabetes and neurological conditions).

- Must agree to submit required specimens for defined translational medicine.

- Must be offered the opportunity to submit additional optional specimens for future, unspecified translational medicine and banking. With consent, specimens must be submitted.

- Must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.